ClinicalTrials.gg
RecruitingNCT05897723Updated Mar 28, 2025

Fractional Radiofrequency for Reduction of Surgical Scar Formation

An interventional study of Fractional Radiofrequency in Surgical Incision, sponsored by Venus Concept. Recruiting at 1 site in United States. Open to female participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Venus Concept · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
Female
01

Study summary

Safety and Efficacy of Fractional Radiofrequency for the Reduction of Surgical Scar Formation

Read the detailed description

The study will evaluate up to 20 subjects scheduled to undergo breast reduction or breast mastectomy in which scar assessment can be made after pre-surgical treatment in a split-body design. The study will involve a single treatment of radiofrequency (RF) applied to one side of the surgical area(s) within 24 hours prior to the procedure. The subject will act as their own control, where one surgical area will be treated, and the other will not be and will act as the control. Tissue samples will be biopsied from the RF treated skin, as well as non-treated skin, at follow up visits. The samples will be used for histological evaluation to assess tissue structure and regeneration following surgery.

02

Conditions studied

  • Surgical Incision

Browse trials for

03

In context

Surgical Wound

315 studies on the registry are indexed under Surgical Wound; 57 are open to participants now.

This study's planned enrollment of 20 is below the median of 66 across 242 interventional studies indexed under Surgical Wound.

Browse Surgical Wound studies →

Lead sponsor

Venus Concept is the lead sponsor of 34 studies on the registry; 4 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 12 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, female subjects 21-75 years of age who are seeking pre-treatment for the prevention of surgical scars.
  2. Able to read, understand and voluntarily provide written .
  3. Able and willing to comply with the treatment/follow-up schedule and requirements.
  4. Willing to avoid direct sunlight to the treatment area for the duration of the study.
  5. Women of child-bearing age are required to be using a reliable method of at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any implantable metal device in the treatment area
  2. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).
  3. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.
  4. Current or history of any kind of cancer, or dysplastic nevi.
  5. Severe concurrent conditions, such as cardiac disorders.
  6. Pregnancy or intending to become pregnant during the study and nursing.
  7. Impaired immune system due to diseases, such as AIDS and , or use of immunosuppressive medications.
  8. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.
  9. Poorly controlled endocrine disorders, such as diabetes.
  10. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
  11. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.
  12. History of bleeding coagulopathies, or use of anticoagulants.
  13. Use of isotretinoin (Accutane®) within six months prior to treatment or at physician discretion.
  14. Treating over tattoo or permanent makeup.
  15. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    All enrolled subjects will undergo breast reduction or breast mastectomy in which scar assessment will be made after pre-surgical treatment in a split-body design, involving a single treatment of RF application to one side of the surgical area(s) within 24 hours prior to the procedure. The subject will act as their own control, where one surgical area will be treated, and the other will not be and will act as the control. Tissue samples will be biopsied from RF treated skin, as well as non-treated skin, at follow up visits. The samples will be used for histological evaluation to assess tissue structure and regeneration following surgery.

    Device: Fractional Radiofrequency

Interventions

  • DeviceFractional Radiofrequency

    Fractional Radiofrequency (RF) delivering nano-fractional RF energy, causing fractional ablation and coagulation at the treatment site.

06

What researchers measure

Primary outcomes

  1. Independent blinded assessment

    Independent blinded evaluator assessment of the surgical scar sites using the Global Aesthetic Improvement Scale (GAIS), comparing follow-up visit photographs for both the treated and untreated sides.

    Time frame: 6-months after treatment

  2. Principle Investigator (PI) evaluation of the scar(s)

    PI evaluation of the scar(s) using the Manchester Scar Scale (MSS) at 3 and 6 months post-treatment for both the treated and untreated sides. Non-invasive skin assessments will be evaluated to document scar morphology, scar thickness/density and colorimetry for both the treated and untreated sides.

    Time frame: 3- and 6-months after treatment

Secondary outcomes

  1. Subject Satisfaction

    Subject satisfaction of treatment using the Subject Satisfaction Scale

    Time frame: 3- and 6-months after treatment

  2. Histological Assessment

    Histological assessment of the treated and the untreated (control) area.

    Time frame: 1-, 3- and 6-months after treatment

  3. Scar Morphology

    Scar morphology will be digitally analyzed using 3D photography camera

    Time frame: Baseline, 3- and 6-months after treatment

  4. Ultrasonography

    High ultrasonography will be used to analyze scar thickness, epidermal thickness and skin density

    Time frame: Baseline, 3- and 6-months after treatment

  5. Colorimetry

    o Colorimetry assessment will be used to establish a clinically acceptable objective assessment of patients' scars

    Time frame: Baseline, 3- and 6-months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD sharing plan.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05897723
Lead sponsor
Venus Concept
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Sep 1, 2023
Primary completion
May 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Mar 28, 2025

Study contacts

Andrea Biro, MSc.
Contact
abiro@venusconcept.com
8889070115
Matthew Gronski, PhD
Contact
mgronski@venusconcept.com
8889070115

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion